Robin Reschke, Max-Eder Research Group Leader at the National Center for Tumor Diseases (NCT), shared a post on LinkedIn:
“Great to be back at EACR in 2026!
Excited to present our work, exchange ideas with this outstanding community of scientists, foster new collaborations, and enjoy the beautiful city of Budapest.
I had the chance to speak about a topic that is close to my heart: immune checkpoint inhibitor-induced toxicities, and how we can better predict, understand, and ultimately prevent these treatment-limiting side effects for our patients.
Looking forward to inspiring discussions, fresh perspectives, and building connections that drive translational cancer research forward. See everybody on the boat tonight.”
More posts featuring Robin Reschke.